Search research articles
Contact Us
Filters
Showing results (61-70 of 129) with videos related to
Page
of 13
Sort By:
BMJ Open
|
September 7, 2021
Study protocol for a randomised controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials (CONSENT)
Abhijit Pal, Sarah Stapleton, Christina Yap, et al.
Molecular Cancer Therapeutics
|
April 3, 2022
Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence-Enabled Studies of Acute Phosphoproteomic Changes
Elizabeth A Coker, Adam Stewart, Bugra Ozer, et al.
Metabolomics : Official Journal of the Metabolomic Society
|
April 15, 2020
Metabolomic changes of the multi (-AGC-) kinase inhibitor AT13148 in cells, mice and patients are associated with NOS regulation
Akos Pal, Yasmin Asad, Ruth Ruddle, et al.
BMC Research Notes
|
May 25, 2012
Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy
Loreta M Rodrigues, Yuen-Li Chung, Nada M S Al Saffar, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 30, 2010
A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attrition
Andre T Brunetto, Joo Ern Ang, David Olmos, et al.
BMC Cancer
|
December 10, 2020
Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease
Dearbhaile Catherine Collins, Raghav Sundar, Anastasia Constantinidou, et al.
BMC Cancer
|
March 9, 2021
Correction to: Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease
Dearbhaile Catherine Collins, Raghav Sundar, Anastasia Constantinidou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 18, 2005
Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies
Udai Banerji, Anne O'Donnell, Michelle Scurr, et al.
Drug Discovery Today
|
December 8, 2009
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
Craig P Carden, Debashis Sarker, Sophie Postel-Vinay, et al.
Journal of Neuro-Oncology
|
April 12, 2018
Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience
Niamh Coleman, Vasiliki Michalarea, Scheryll Alken, et al.
Page
of 13
Search research articles
Search
Showing results (61-70 of 129) with videos related to
Sort By:
Page
of 13
BMJ Open
|
September 7, 2021
Study protocol for a randomised controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials (CONSENT)
Abhijit Pal, Sarah Stapleton, Christina Yap, et al.
Molecular Cancer Therapeutics
|
April 3, 2022
Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence-Enabled Studies of Acute Phosphoproteomic Changes
Elizabeth A Coker, Adam Stewart, Bugra Ozer, et al.
Metabolomics : Official Journal of the Metabolomic Society
|
April 15, 2020
Metabolomic changes of the multi (-AGC-) kinase inhibitor AT13148 in cells, mice and patients are associated with NOS regulation
Akos Pal, Yasmin Asad, Ruth Ruddle, et al.
BMC Research Notes
|
May 25, 2012
Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy
Loreta M Rodrigues, Yuen-Li Chung, Nada M S Al Saffar, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 30, 2010
A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attrition
Andre T Brunetto, Joo Ern Ang, David Olmos, et al.
BMC Cancer
|
December 10, 2020
Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease
Dearbhaile Catherine Collins, Raghav Sundar, Anastasia Constantinidou, et al.
BMC Cancer
|
March 9, 2021
Correction to: Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease
Dearbhaile Catherine Collins, Raghav Sundar, Anastasia Constantinidou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 18, 2005
Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies
Udai Banerji, Anne O'Donnell, Michelle Scurr, et al.
Drug Discovery Today
|
December 8, 2009
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
Craig P Carden, Debashis Sarker, Sophie Postel-Vinay, et al.
Journal of Neuro-Oncology
|
April 12, 2018
Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience
Niamh Coleman, Vasiliki Michalarea, Scheryll Alken, et al.
Page
of 13